Intelligence Profile
Clinical Applications
Clinical Applications of AAV9-Follistatin
AAV9-Follistatin is currently under investigation for its potential use in addressing age-related muscle loss. The therapy is part of a clinical trial named CALM-AF-AI, which combines AAV9-Follistatin with a VEGF plasmid gene therapy to promote muscle growth and vascular health. This trial targets counteracting muscle atrophy linked to aging by enhancing muscle mass and strength while potentially improving blood supply to the muscles.
As of now, there are no published results from this trial as it is still in the recruiting phase. Without further data or completed studies, detailed conclusions on the efficacy and safety of AAV9-Follistatin for age-related muscle loss remain pending. This indicates an evolving field with promising potential, but concrete clinical applications are yet to be established based on trial outcomes.
Disclaimer: This information is educational and should not substitute professional medical advice. Consult a healthcare provider for personalized guidance.